DrugPatentWatch Database Preview

Details for Patent: 9,243,245

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,243,245 protect, and when does it expire?

Patent 9,243,245 protects EXONDYS 51 and is included in one NDA.

This patent has sixty-seven patent family members in seventeen countries.

Summary for Patent: 9,243,245

Title:	Means and methods for counteracting muscle disorders
Abstract:	The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
Inventor(s):	De Kimpe; Josephus Johannes (Utrecht, NL), Platenburg; Gerard Johannes (Voorschoten, NL), Van Deutekom; Judith Christina Theodora (Dordrecht, NL), Aartsma-Rus; Annemieke (Hoofddorp, NL), Van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL)
Assignee:	Academisch Ziekenhuis Leiden (Leiden, NL) BioMarin Technologies B.V. (Leiden, NL)
Application Number:	12/767,702
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Device;

Drugs Protected by US Patent 9,243,245

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes				Y		TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes				Y		INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes				Y		TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes				Y		INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

Foreign Priority and PCT Information for Patent: 9,243,245

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07119351	Oct 26, 2007

International Family Members for US Patent 9,243,245

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008317566
Australia	2009310557
Australia	2009310558
Canada	2704049
Canada	2741629
Canada	2741793
Canada	3017539